Analyst
Wolfe Research
Equibles does not estimate personal net worth.
Brendan is recorded as Analyst at Wolfe Research. Brendan has spoken on 3 earnings calls across 2 companies, most recently for Vistance Networks, Inc. on February 26, 2026. Those appearances were for Crinetics Pharmaceuticals, Inc. and Vistance Networks, Inc. (VISN). The companies whose calls Brendan spoke on are classified in the Healthcare and Technology sectors.
“Is there anything that you guys can share about that? And then could you give a sense for the magnitude of the E&O benefits for Ruckus, either year over year or quarter over quarter?”
“In the opening remarks, you mentioned aiming to position past Sonify as a first-line therapy, but we're curious to know how you expect to do that with generics currently on the market.”
“You stated earlier that acromegaly patients see endos two to four times a year. which could lead to a slower start to the launch. But shouldn't this approval draw patients to see their docs regardless of their cadence throughout the year?”
Wolfe Research
Analyst
Transcript header (unverified)
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
Communication Equipment · Technology
Crinetics Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.
